PriceTargets.com logo

Indivior - INDV Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 31.80%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$12.14 As of 12/30/2024 12:45 PM ET
▼ -0.24 (-1.94%)

This chart shows the closing price for INDV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Indivior Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INDV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INDV

Analyst Price Target is $16.00
▲ +31.80% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Indivior in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 31.80% upside from the last price of $12.14.

This chart shows the closing price for INDV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Indivior.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/25/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$15.00 ➝ $16.00
10/11/2024Craig HallumLower TargetBuy ➝ Buy$20.00 ➝ $16.00
10/11/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$22.00 ➝ $15.00
9/13/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$22.00 ➝ $22.00
7/23/2024Piper SandlerInitiated CoverageOverweight$22.00
7/10/2024Craig HallumLower TargetBuy ➝ Buy$37.00 ➝ $24.00
4/3/2024Craig HallumInitiated CoverageBuy$37.00
7/13/2023Northland SecuritiesInitiated CoverageOutperform$35.00
(Data available from 12/30/2019 forward)

News Sentiment Rating

1.04 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 7 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 6 very positive mentions
  • 70 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
9/1/2024
  • 9 very positive mentions
  • 73 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 7 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Indivior logo
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More

Today's Range

Now: $12.14
Low: $12.07
High: $12.17

50 Day Range

MA: $10.61
Low: $8.27
High: $12.38

52 Week Range

Now: $12.14
Low: $7.33
High: $23.22

Volume

106,431 shs

Average Volume

585,655 shs

Market Capitalization

$1.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Indivior?

The following Wall Street analysts have issued reports on Indivior in the last twelve months: Craig Hallum, and Piper Sandler.
View the latest analyst ratings for INDV.

What is the current price target for Indivior?

0 Wall Street analysts have set twelve-month price targets for Indivior in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 31.8%. Craig Hallum has the highest price target set, predicting INDV will reach $16.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $16.00 for Indivior in the next year.
View the latest price targets for INDV.

What is the current consensus analyst rating for Indivior?

Indivior currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INDV will outperform the market and that investors should add to their positions of Indivior.
View the latest ratings for INDV.

What other companies compete with Indivior?

Other companies that are similar to Indivior include Legend Biotech, Nuvalent, Elanco Animal Health, Cytokinetics and Blueprint Medicines. Learn More about companies similar to Indivior.

How do I contact Indivior's investor relations team?

Indivior's physical mailing address is 10710 Midlothian Turnpike, North Chesterfield, VA 23235, United States. The company's listed phone number is 804-379-1090 and its investor relations email address is [email protected]. The official website for Indivior is www.indivior.com. Learn More about contacing Indivior investor relations.